OvaRex flunks Phase III ovarian cancer trials

United Therapeutics announced that two Phase III trials of OvaRex, an ovarian cancer treatment, failed to reach statistical significance. The two trials sought to confirm earlier data which suggested that OvaRex could extend the time to disease relapse among patients who had successfully completed front-line therapy. United Therapeutics said it would continue to analyze the preliminary data.

"Given what appeared to be the promising clinical activity observed in a subset of patients from an earlier phase II trial, we are very surprised by these findings," said Christopher Nicodemus, MD, Senior Vice President Clinical Research & Development.

- see this release for more

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.